Adbry/Adtralza (LEO Pharma) Market Research Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts, 2020-2025, 2025-2030F, 2035F

(MENAFN- GlobeNewsWire - Nasdaq) Key opportunities in the Adbry/Adtralza market include rising adoption of targeted dermatology biologics, expansion into pediatric use, increased healthcare spending, and heightened demand for effective atopic dermatitis treatments. Growth is driven by higher prevalence of eczema, innovation in IL-13 therapies, and regional manufacturing.

Dublin, May 07, 2026 (GLOBE NEWSWIRE) -- The "Adbry/Adtralza Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets's offering.

The Adbry/Adtralza market has seen significant growth due to limitations of topical corticosteroids and increasing prevalence of atopic dermatitis. The success of monoclonal antibody treatments, coupled with dermatologist acceptance of biologics and regulatory approvals for IL-targeted therapies, further solidifies this growth trajectory.

Anticipated advancements in the coming years include a growing eczema patient population, expansion into pediatric use, and improved reimbursement coverage. There is an increasing awareness of biologic therapies, alongside continued innovation in dermatology biologics. Major trends point to rising adoption of targeted therapies, especially in moderate to severe cases of atopic dermatitis, and an expansion of IL-13 targeted therapies, with a notable demand for steroid-sparing treatments.

Atopic dermatitis, a chronic inflammatory skin disorder, significantly drives the Adbry/Adtralza market. Factors such as air pollution, urban lifestyles, and genetic susceptibilities contribute to its rising occurrence. Adbry/Adtralza, targeting the interleukin-13 (IL-13) pathway, reduces inflammation and immune responses, providing relief from symptoms. As per the National Library of Medicine, the global prevalence of this condition stands at 2.6%, impacting over 204 million individuals worldwide. This growing prevalence is anticipated to further fuel market growth.

Increasing healthcare expenditure is expected to support the expansion of the Adbry/Adtralza market by improving access to innovative therapies. Notably, healthcare spending enhances the distribution of advanced biologic treatments for conditions like atopic dermatitis. A report by the Office for National Statistics recorded a notable increase in healthcare expenditure, bolstering the market for Adbry/Adtralza.

Leading companies in the Adbry/Adtralza market are focusing on developing biologic therapies that inhibit IL-13 to optimize treatment outcomes. A significant milestone was Leo Pharma's announcement regarding the FDA's expanded approval of Adbry for use in pediatric patients, making it the first and only biologic designed to inhibit IL-13 in atopic dermatitis treatment.

North America holds the largest market share, while Asia Pacific is set to experience the fastest growth. The market spans various regions, including Western and Eastern Europe, South America, and the Middle East, covering major countries such as the USA, China, and Germany.

Key Technologies & Future Trends

• Biotechnology, Genomics & Precision Medicine
• Rising Adoption of Targeted Dermatology Biologics
• Growing Use in Moderate to Severe Atopic Dermatitis
• Expansion of IL 13 Targeted Therapies
• Increasing Long Term Maintenance Biologic Therapy
• Higher Patient Demand for Steroid Sparing Treatments

Report Scope:

• Indication: Atopic Dermatitis; Other Dermatological Conditions
• Distribution Channel: Hospital and Clinics; Retail and Specialty Pharmacies
• End User: Adult Patients; Geriatric Patients

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN07052026004107003653ID1111082056